fulvestrant,ribociclib
novartis
['natalee', ' fulv', 'kisqali', 'breast', 'novartis']
novartis' kisqali as adjuvant treatment benefits early hr-positive, node-negative breast cancer patients. data from the natalee trial, reported at the asco annual meeting, will likely make kisqali plus fulvestrant a new option for this subset of patients. 